We have located links that may give you full text access.
Journal Article
Review
Renin inhibition--benefit beyond hypertension control.
The importance of the renin angiotensin system (RAS) in blood pressure and electrolyte regulation has been well established. High RAS activity results in over-activation of the angiotensin AT1-receptor by its substrate, angiotensin II (AII), leading to increases in BP and direct growth-promoting effects on tissues that result in end-organ damage. The antihypertensive therapies, such as ACE inhibitors and angiotensin AT1-receptor blockers (ARBs) have proved to be successful treatments for hypertension, heart failure, and other related cardiovascular and renal disorders. However, these compounds do not completely inhibit the RAS as a result of AII formation by indirect pathways and compensatory feedback mechanisms, resulting in renin release. Thus renin inhibition has been identified as the preferred pharmacologic approach to blockade of the renin-angiotensin system. The advantages of inhibiting renin in the RAS have been recognized for almost half a century; however major advances in the development of potential clinically effective renin inhibitors have been made only in the past few years with the approval of Aliskiren for clinical use.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app